Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.
Department of Diagnostic Pathology and Cytology, Osaka International Cancer Center Institute, 3-1-69, Otemae, Chuo-Ku, 541-8567, Japan.
Auris Nasus Larynx. 2024 Aug;51(4):755-760. doi: 10.1016/j.anl.2024.05.007. Epub 2024 Jun 8.
While several studies reported epidermal growth factor receptor (EGFR) expression in salivary gland cancer (SGC), results varied due to a lack of unified definition of EGFR positivity. In this study, we assessed the EGFR expression level using both EGFR positive score and cumulative EGFR score in the patients with SGC.
Between January 2010 and April 2021, 102 patients with SGC who underwent surgical resection were reviewed retrospectively by immunohistochemistry. The membrane staining intensity was scored as follows: no staining (0), weak staining (1+), intermediate staining (2+), and strong staining (3+). The cumulative EGFR score was determined on a continuous scale of 0-300 using the formula:1 × (1+: percentage of weakly stained cells) + 2 × (2+: percentage of moderately stained cells) + 3 × (3+: percentage of strongly stained cells).
EGFR expression in SGC varied widely even among the same as well as different histopathological types. The average EGFR positive scores were 46.0 %, 55.7 %, 51.6 %, 1.0 %, 26.8 %, 50 %, and 76.8 % for mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (AcCC), adenocarcinoma NOS (ACNOS), carcinoma ex pleomorphic adenoma (CAexPA), and squamous cell carcinoma (SqCC), respectively. The average cumulative EGFR scores were 82, 91, 80, 1, 52, 93, and 185 for MEC, SDC, AdCC, AcCC, ACNOS, CAexPA, and SqCC, respectively.
EGFR positive scores and cumulative EGFR scores in SGCs varied among the various histological types, and even in the same histological type. These scores may predict the clinical outcome of SGC treated with EGFR-targeting therapies, such as head and neck photoimmunotherapy, and need to be evaluated in future studies.
尽管有几项研究报道了唾液腺癌(SGC)中表皮生长因子受体(EGFR)的表达,但由于缺乏 EGFR 阳性的统一定义,结果存在差异。在本研究中,我们使用 EGFR 阳性评分和累积 EGFR 评分评估了 SGC 患者的 EGFR 表达水平。
回顾性分析 2010 年 1 月至 2021 年 4 月期间接受手术切除的 102 例 SGC 患者,采用免疫组织化学法进行检测。膜染色强度评分如下:无染色(0)、弱染色(1+)、中度染色(2+)和强染色(3+)。累积 EGFR 评分通过公式计算得出,范围为 0-300,公式为:1×(1+:弱阳性细胞百分比)+2×(2+:中度染色细胞百分比)+3×(3+:强染色细胞百分比)。
即使在同一组织学类型和不同组织学类型的 SGC 中,EGFR 的表达也存在很大差异。黏液表皮样癌(MEC)、涎管癌(SDC)、腺样囊性癌(AdCC)、腺泡细胞癌(AcCC)、非特异性腺癌(ACNOS)、癌在多形性腺瘤中(CAexPA)和鳞状细胞癌(SqCC)的平均 EGFR 阳性评分分别为 46.0%、55.7%、51.6%、1.0%、26.8%、50%和 76.8%。MEC、SDC、AdCC、AcCC、ACNOS、CAexPA 和 SqCC 的平均累积 EGFR 评分分别为 82、91、80、1、52、93 和 185。
SGC 中 EGFR 阳性评分和累积 EGFR 评分在不同组织学类型之间存在差异,甚至在同一组织学类型中也存在差异。这些评分可能预测接受 EGFR 靶向治疗(如头颈部光免疫治疗)的 SGC 患者的临床结局,需要在未来的研究中进行评估。